Kodiak Sciences Inc (KOD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $32.28 (-1.74%), Market cap $2.32B, 52-week low–high $3.40 ~ $46.44.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- inte
Financial statements, price targets, institutional (13F) holdings and related news for Kodiak Sciences Inc are updated in real time on BlackAll Trade.
Kodiak Sciences Inc trades at $32.28 (-1.74%). Real-time quotes and charts are available on BlackAll Trade.
Kodiak Sciences Inc has a market cap of about $2.32B.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is t